1496-VIDA:基于病毒蛋白酶触发细胞裂解的通用型mRNA抗病毒疗法 episode artwork

EPISODE · Aug 27, 2026 · 16 MIN

1496-VIDA:基于病毒蛋白酶触发细胞裂解的通用型mRNA抗病毒疗法

from 聊聊Sci

该研究介绍了一种名为 VIDA 的创新型通用抗病毒 mRNA 疗法,其核心机制是利用病毒蛋白酶触发受感染细胞的裂解性死亡。研究人员通过基因工程改造微管蛋白 (GSDM),将其内部的天然切割位点替换为特定病毒的蛋白酶识别序列,从而使药物仅在病毒存在时才会被激活。这种“杀伤并预警”的策略不仅能精准清除被感染的细胞,还能释放免疫信号以激活机体的保护性免疫反应。实验证明,该平台在应对甲肝病毒 (HAV)、寨卡病毒 (ZIKV) 以及 新冠病毒 (SARS-CoV-2) 等多种病毒时表现出显著的有效性。此外,团队还引入了生成式人工智能 (AI) 来优化设计,进一步提升了该疗法的安全性和抗病毒效能。References:Li L, Yan X L, Wang H Y, et al. Viral protease-initiated lytic cell death as a universal antiviral mRNA therapy[J]. Cell, 2026.前往小宇宙评论区与主播互动

Episode metadata supplied by the publisher feed · Published Aug 27, 2026

Embed this episode

Ready to play

1496-VIDA:基于病毒蛋白酶触发细胞裂解的通用型mRNA抗病毒疗法

0:00 16:21

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of 聊聊Sci?

This episode is 16 minutes long.

When was this 聊聊Sci episode published?

This episode was published on August 27, 2026.

Can I download this 聊聊Sci episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!